# Infectious Diseases Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN
- Date: 2026-02-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Leticia Navarro, MD
- Calendar frame: modern shifted

- Requested by: Martin Beaumont, MD

## Reason for consultation

New cavitary, smear-positive pulmonary tuberculosis in a 21-year-old dentist who drinks heavily. Please confirm the regimen and doses, advise on liver monitoring given his alcohol use, and advise on isolation, return to dental work, and the length of treatment. **S**

## History

Mr. Holliday, a 21-year-old dentist, is seen at the request of Dr. Beaumont two weeks after a diagnosis of cavitary pulmonary tuberculosis. He has taken all thirteen doses of isoniazid, rifampin, pyrazinamide, and ethambutol with pyridoxine by video-observed therapy. His cough and night sweats are improving and the hemoptysis has stopped. He has mild nausea after the morning doses and orange urine and tears, and no jaundice, abdominal pain, rash, numbness, or vision change. He has cut his drinking down sharply. He has no travel outside the country, no known contact with drug-resistant tuberculosis, and no immune-suppressing condition or medicine. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin; temperature 37.3 °C, heart rate 92; seen in a negative-pressure room |
| Eyes | No icterus; visual acuity and color vision normal |
| Respiratory | Coarse crackles and bronchial breathing over the right upper zone |
| Abdomen | Soft, non-tender; liver not enlarged |
| Neurological | Normal sensation in the feet |
| Skin | No rash |

BP 114/72 mmHg; pulse 92 bpm; respirations 18/min; temperature 37.3 °C; oxygen saturation 96% on room air; weight 59 kg; BMI 18.6 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Beaumont's diagnostic note; the chest X-ray; the three baseline smears and the nucleic acid amplification result; today's report that the baseline cultures are growing Mycobacterium tuberculosis complex, with susceptibility pending; the HIV, hepatitis B, and hepatitis C results, all negative, with no hepatitis B immunity; and today's liver tests and vision check. ALT: 41 U/L; AST: 39 U/L; Total bilirubin: 0.7 mg/dL; Visual acuity, right eye (ETDRS letters): 85; Visual acuity, left eye (ETDRS letters): 84; AUDIT-C: 4. All results are synthetic.

## Assessment

1. **Cavitary pulmonary tuberculosis, probably drug-susceptible** (A15.0). Smear-positive, culture-positive cavitary disease with an early clinical response and full adherence. No rifampin resistance on the molecular test; isoniazid susceptibility is pending. The regimen and the weight-band doses are correct: isoniazid about 5 mg/kg, rifampin about 10 mg/kg, pyrazinamide 1500 mg and ethambutol 1200 mg for 56 to 75 kg. HIV negative. **S**
2. **Liver risk**. Heavy drinking, low albumin, and the three hepatotoxic drugs together raise his risk of drug-induced liver injury. Today's ALT 41, AST 39, and bilirubin 0.7 are normal. Injury is defined as ALT at least three times the upper limit with symptoms, or at least five times without symptoms, or a bilirubin rise; small rises below this are common and do not need the drugs stopped. **S**
3. **Infectiousness and return to work**. He remains infectious until he has three negative sputum smears, a clinical response, and at least two weeks of effective treatment. Because he works close to patients' faces, return should wait for all three. **S**
4. **Length of treatment**. Six months in total if the two-month culture is negative. A cavity on the first X-ray together with a positive two-month culture would extend the continuation phase to seven months. The four-month rifapentine and moxifloxacin regimen is an alternative only at the start of treatment; switching now offers no benefit. **S**
5. **Alcohol use disorder, mild** (F10.10). Stopping alcohol is the most useful thing he can do for his liver during treatment. If medication is wanted, acamprosate is preferred, because it is not processed by the liver; naltrexone and disulfiram are best avoided while he is on hepatotoxic drugs. **S**

## Recommendations

1. Continue isoniazid 300 mg, rifampin 600 mg, pyrazinamide 1500 mg, ethambutol 1200 mg, and pyridoxine 50 mg daily by video-observed therapy, seven days a week, for the 56-dose intensive phase; bedtime dosing with a snack for the nausea.
2. Stop ethambutol once the isolate is shown to be susceptible to isoniazid and rifampin.
3. Visual acuity and color vision monthly while on ethambutol.
4. Liver tests monthly throughout treatment because of his drinking, and at once for any nausea, vomiting, abdominal pain, jaundice, or dark urine; the health department nurse should hold doses for those symptoms until results are back.
5. Stop all hepatotoxic drugs if ALT reaches three times the upper limit with symptoms, or five times without, and call me.
6. Three sputum smears on consecutive mornings in the third week; release from home isolation and return to dental work when all three are negative, with continued clinical improvement.
7. Sputum smear and culture monthly until two consecutive cultures are negative, including a culture at the end of the intensive phase.
8. Continuation phase of isoniazid and rifampin for four months if the two-month culture is negative, or seven months if it is positive.
9. No alcohol during treatment; counseling with a substance-use counselor; acamprosate if medication is wanted.
10. Hepatitis B vaccination, which can wait until treatment ends.
11. I will review the results by message at two months and at the end of treatment; no infectious diseases visit is needed unless the cultures stay positive, a drug must be stopped, or resistance is found.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Beaumont, who sees him the same day, and with the health department tuberculosis nurse who supervises his video-observed therapy. The plan, the warning symptoms of liver injury, and the criteria for returning to work were explained to Mr. Holliday, who agreed with them. **S**

## Follow-up

Results review by message at two months and at the end of treatment; sooner for liver injury, persistent positive cultures, or drug resistance. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025), American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America (American Journal of Respiratory and Critical Care Medicine)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
